Last edition
News about "HP518"
Hinova Pharma Secures FDA Fast Track Designation for HP518
Hinova Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for HP518, an investigational drug for the treatment of Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC).
HP518 | 08/07/2024 | By Aishwarya | 211
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members